Skip to main content

Table 3 Relative cost and effects of the cost effectiveness analysis shown for the three different estimates on current recourse to malaria chemoprophylaxis

From: Cost-effectiveness analysis of malaria chemoprophylaxis for travellers to West-Africa

Cost-effectiviness analysis with the three different estimated 'recourse to malaria chemoprophylaxis'

55%

68.70%

82.40%

 

Current situation of no reimbursement

80% reimbursement strategy

Current situation of no reimbursement

80% reimbursement strategy

Current situation of no reimbursement

80% reimbursement strategy

Cost per journey (€)

(95% CI)

65.45

(47.88 - 86.03)

50.94

(41.25 - 62.36)

50.05

(36.76 - 65.50)

45.36

(37.38 - 54.96)

36.64

(25.49 - 45.46)

39.78

(33.42 - 47.74)

Effect per journey (%) (95% CI) = probabilty of contracting malaria

0.01196 (0.00861 - 0.01587)

0.00625 (0.00445 -0.00836)

0.00891 (0.00640 - 0.01184)

0.00494 (0.00348 - 0.00669)

0.00586 (0.00417 - 0.00786)

0.00363 (0.00249 - 0.00506)

Cost Effectiveness ratio (€)

      

   Per case of malaria prevented

-

8'151

-

9'186

-

10'969

   Per malaria related death prevented

-

679'250

-

765'490

-

914'045

Incremental cost (€) of 80% reimbursement strategy

      

   Per additional malaria case prevented

Reference strategy

dominant

Reference strategy

dominant

Reference strategy

2'302

   Per additional malaria related death prevented

Reference strategy

dominant

Reference strategy

dominant

Reference strategy

191'833